

# Piers A Blombery

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7134204/publications.pdf>

Version: 2024-02-01

72  
papers

1,984  
citations

331538

21  
h-index

265120

42  
g-index

74  
all docs

74  
docs citations

74  
times ranked

3112  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019, 9, 342-353.                    | 7.7  | 306       |
| 2  | Dynamic molecular monitoring reveals that SWI5H9SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.                                 | 15.2 | 147       |
| 3  | Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019, 10, 2385.  | 5.8  | 139       |
| 4  | First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. <i>Cancer Discovery</i> , 2019, 9, 1036-1049.           | 7.7  | 129       |
| 5  | Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e387-e390.                                       | 1.7  | 124       |
| 6  | Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020, 135, 773-777.  | 0.6  | 115       |
| 7  | Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. <i>Blood</i> , 2021, 138, 1391-1405.   | 0.6  | 87        |
| 8  | BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.  | 0.6  | 67        |
| 9  | Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. <i>Haematologica</i> , 2012, 97, 780-783.  | 1.7  | 63        |
| 10 | Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018, 9, 36126-36136.                      | 0.8  | 62        |
| 11 | Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. <i>Blood Advances</i> , 2018, 2, 335-346.   | 2.5  | 47        |
| 12 | Erdheim-Chester Disease Harboring the BRAF V600E Mutation. <i>Journal of Clinical Oncology</i> , 2012, 30, e331-e332.  | 0.8  | 46        |
| 13 | High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.  |      | 45        |
| 14 | Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.  | 2.5  | 39        |
| 15 | Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e188-e191.   | 1.2  | 37        |
| 16 | Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.  | 2.5  | 34        |
| 17 | Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.  | 0.6  | 34        |
| 18 | BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019, 134, 170-170. | 0.6  | 33        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 895-899.  | 1.0 | 28        |
| 20 | Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 59S-64S.  | 0.7 | 28        |
| 21 | Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. <i>Annals of Hematology</i> , 2011, 90, 1167-1172.                                     | 0.8 | 27        |
| 22 | The molecular pathogenesis of B-cell non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 280-293.  | 1.1 | 22        |
| 23 | Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies. <i>Journal of Clinical Pathology</i> , 2018, 71, 84-87.   | 1.0 | 18        |
| 24 | Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. <i>Annals of Hematology</i> , 2017, 96, 725-732. | 0.8 | 17        |
| 25 | CN spectator: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. <i>Scientific Reports</i> , 2019, 9, 6426.  | 1.6 | 17        |
| 26 | Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing. <i>Haematologica</i> , 2020, 106, 313-315.  | 1.7 | 17        |
| 27 | Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. <i>Blood Advances</i> , 2022, 6, 503-508.   | 2.5 | 16        |
| 28 | Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , 2019, 49, 152-159.   | 0.5 | 15        |
| 29 | Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 257-262.  | 0.6 | 15        |
| 30 | Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. <i>HemaSphere</i> , 2019, 3, e187.  | 1.2 | 14        |
| 31 | Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.   | 2.5 | 14        |
| 32 | Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. <i>Haematologica</i> , 2020, 106, 64-73.   | 1.7 | 14        |
| 33 | A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. <i>British Journal of Haematology</i> , 2020, 190, e297-e301.   | 1.2 | 14        |
| 34 | Myeloid somatic mutation panel testing in myeloproliferative neoplasms. <i>Pathology</i> , 2021, 53, 339-348.   | 0.3 | 13        |
| 35 | Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.   | 0.6 | 13        |
| 36 | Transient, flexible gene editing in zebrafish neutrophils and macrophages for determination of cell-autonomous functions. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .  | 1.2 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | CAR-T cell therapy: practical guide to routine laboratory monitoring. <i>Pathology</i> , 2021, 53, 408-415.  | 0.3 | 10        |
| 38 | Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. <i>Blood</i> , 2020, 136, 43-44.                                    | 0.6 | 9         |
| 39 | Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 606-612.                         | 1.2 | 8         |
| 40 | Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay. <i>British Journal of Haematology</i> , 2018, 183, 146-149. | 1.2 | 8         |
| 41 | Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. <i>British Journal of Haematology</i> , 2021, 195, 113-118.  | 1.2 | 8         |
| 42 | T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2857-2859.                                | 1.3 | 7         |
| 43 | Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2024-2026.   | 0.6 | 6         |
| 44 | Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques. <i>Leukemia and Lymphoma</i> , 2014, 55, 19-30.  | 0.6 | 5         |
| 45 | Primary Breast Lymphoma: Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .  | 3.0 | 5         |
| 46 | Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. <i>Blood</i> , 2018, 131, 699-702.  | 0.6 | 5         |
| 47 | Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 123-126.  | 1.2 | 5         |
| 48 | Canary: an atomic pipeline for clinical amplicon assays. <i>BMC Bioinformatics</i> , 2017, 18, 555.  | 1.2 | 4         |
| 49 | Diagnostic evaluation and considerations in hypocellular bone marrow failure: A focus on genomics. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 82-89.  | 0.7 | 4         |
| 50 | A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC). <i>Blood</i> , 2020, 136, 34-35.   | 0.6 | 4         |
| 51 | Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. <i>European Journal of Haematology</i> , 2022, 108, 469-485.   | 1.1 | 4         |
| 52 | Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. <i>Leukemia and Lymphoma</i> , 2018, 59, 992-995.                 | 0.6 | 2         |
| 53 | Recovery of natural killer cell cytotoxicity in a A91V perforin homozygous patient following severe haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2020, 190, 458-461.                                       | 1.2 | 2         |
| 54 | Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants. <i>Leukemia and Lymphoma</i> , 2020, 61, 1257-1259.  | 0.6 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 2582-2590.                          | 1.3 | 2         |
| 56 | High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 15-16.   | 0.6 | 2         |
| 57 | Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing. <i>Blood</i> , 2020, 136, 39-40.   | 0.6 | 2         |
| 58 | Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. <i>BMC Medical Genomics</i> , 2022, 15, 70.  | 0.7 | 2         |
| 59 | Methylâ€CpG binding domain 4, DNA glycosylase ( <sc>MBD4</sc> )â€associated neoplasia syndrome associated with a homozygous missense variant in <i>MBD4</i> : Expansion of an emerging phenotype. <i>British Journal of Haematology</i> , 2022, , . | 1.2 | 2         |
| 60 | Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. <i>Pathology</i> , 2022, , .  | 0.3 | 2         |
| 61 | Copper deficiency mimicking myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 1223-1226.   | 0.6 | 1         |
| 62 | The price of success-health economics of personalized diffuse large B-cell lymphoma treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 1517-1519.  | 0.6 | 1         |
| 63 | Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. <i>Leukemia and Lymphoma</i> , 2021, 62, 3060-3062.  | 0.6 | 1         |
| 64 | Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.  | 0.6 | 1         |
| 65 | Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 279-280.  | 0.6 | 0         |
| 66 | What does good FISHing look like in MDS?. <i>Leukemia and Lymphoma</i> , 2019, 60, 571-572.   | 0.6 | 0         |
| 67 | Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. <i>Pathology</i> , 2021, 53, 487-492.   | 0.3 | 0         |
| 68 | Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. <i>Blood</i> , 2018, 132, 3867-3867.      | 0.6 | 0         |
| 69 | Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy. <i>Blood</i> , 2019, 134, 4290-4290.   | 0.6 | 0         |
| 70 | Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2021, 138, 4387-4387.  | 0.6 | 0         |
| 71 | Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia. <i>Blood</i> , 2020, 136, 5-6.   | 0.6 | 0         |
| 72 | Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2020, 136, 23-23.   | 0.6 | 0         |